April 2000
Worldwide Biotech;Apr2000, Vol. 12 Issue 4, p1
Trade Publication
Reports that the United States Food and Drug Administration has approved a testosterone replacement gel manufactured by Unimed Pharmaceuticals for hypogonadism.


Related Articles

  • Unimed's Androgel NDA Filed With FDA for 12-Month Review.  // Biotech Business;Sep99, Vol. 12 Issue 9, p1 

    Reports that Unimed Pharmaceuticals, Inc. has announced that its New Drug Application (NDA) for Androgel testosterone gel has been filed with the United States Food and Drug Administration. Purpose of Androgel (TM); Symptoms of hypogonadism; Drugs marketed by Unimed Pharmaceuticals, Inc.

  • THERE'S THE RUB. Pfeiffer, Naomi // Drug Topics;3/20/2000, Vol. 144 Issue 6, p31 

    Reports on the approval by the United States Food and Drug Administration of AndroGel, a testosterone gel for treating hypogonadism developed by Unimed Pharmaceuticals. Application of the gel; Marketing of AndroGel; Results of the clinical trial of the drug.

  • FDA approves testosterone gel for hypogonadism.  // Endocrine Today;Jan2011, Vol. 9 Issue 1, p31 

    This article reports on the decision of the U.S. Food and Drug Administration (FDA) to approve a clear, odorless gel for the treatment of hypogonadism.

  • Pharma: Other News To Note.  // BioWorld Today;9/6/2013, Vol. 24 Issue 171, p12 

    The article reports that the U.S. Food and Drug Administration (FDA) has accepted a complete response submission for its treatment for hypogonadism in men Aveed from Endo Pharmaceuticals Inc. in September 2013.

  • New testosterone patch targets male hypogonadism. Rodgers, Katie // Drug Topics;11/6/95, Vol. 139 Issue 21, p44 

    Reports that Food and Drug Administration has cleared Androderm (testosterone transdermal system) for `for testosterone replacement therapy in men for conditions associated with deficiency or absence of endogenous testosterone.' Treatment of male hypoganidism; Cause of male hypogonadism.

  • FDA, Repros meeting: no new safety trials due for Androxal. Osborne, Randy // BioWorld Today;2/10/2014, Vol. 25 Issue 27, p1 

    The article reports on the meeting held between Repros Therapeutics Inc. and the U.S. Food and Drug Administration (FDA). The FDA agreed in the meeting that Repros Therapeutics Inc. will not need new safety tests before submitting the new drug application (NDA) for its Androxal (enclomiphene)...

  • Acrux signs the biggest deal in biotech yet.  // Australasian Biotechnology;Jul2010, Vol. 20 Issue 2, p7 

    The article reports on the deal signed by Acrux with Eli Lilly to commercialize its Axiron, a drug for low-testosterone in hypogonadal men. The Phase 3 trials of the solution have been completed and the U.S. Food and Drug Administration (FDA) put the product for substantive review. Under the...

  • Urologist Mark Sigman, MD, addresses FDA panel on testosterone replacement therapy.  // Rhode Island Medical Journal;Nov2014, Vol. 97 Issue 11, p51 

    The article focuses on a joint meeting of the Bone, Reproductive and Urologic Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee of the U.S. Food and Drug Administration (FDA) in which the combined advisory panel discussed who should receive testosterone...

  • Indevus Files For FDA Approval For Long-Acting Testosterone. Shrine, Jim // BioWorld Today;8/29/2007, Vol. 18 Issue 168, p1 

    The article reports that Indevus Pharmaceuticals Inc. has filed for U.S. Food and Drug Administration (FDA) approval for Nebido, an injectable three-month formulation of testosterone for treating hypogonadism. Indevus has acquired rights to Nebido in July 2005 in a deal with Schering AG. Indevus...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics